These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 21987746)

  • 1. Protective efficacy of a bivalent recombinant vesicular stomatitis virus vaccine in the Syrian hamster model of lethal Ebola virus infection.
    Tsuda Y; Safronetz D; Brown K; LaCasse R; Marzi A; Ebihara H; Feldmann H
    J Infect Dis; 2011 Nov; 204 Suppl 3(Suppl 3):S1090-7. PubMed ID: 21987746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emergency postexposure vaccination with vesicular stomatitis virus-vectored Ebola vaccine after needlestick.
    Lai L; Davey R; Beck A; Xu Y; Suffredini AF; Palmore T; Kabbani S; Rogers S; Kobinger G; Alimonti J; Link CJ; Rubinson L; Ströher U; Wolcott M; Dorman W; Uyeki TM; Feldmann H; Lane HC; Mulligan MJ
    JAMA; 2015 Mar 24-31; 313(12):1249-55. PubMed ID: 25742465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vesicular stomatitis virus-based vaccine protects hamsters against lethal challenge with Andes virus.
    Brown KS; Safronetz D; Marzi A; Ebihara H; Feldmann H
    J Virol; 2011 Dec; 85(23):12781-91. PubMed ID: 21917979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bivalent VSV Vectors Mediate Rapid and Potent Protection from Andes Virus Challenge in Hamsters.
    Marceau J; Safronetz D; Martellaro C; Marzi A; Rosenke K; Feldmann H
    Viruses; 2024 Feb; 16(2):. PubMed ID: 38400054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirus.
    Mire CE; Geisbert JB; Marzi A; Agans KN; Feldmann H; Geisbert TW
    PLoS Negl Trop Dis; 2013; 7(12):e2600. PubMed ID: 24367715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus.
    Geisbert TW; Geisbert JB; Leung A; Daddario-DiCaprio KM; Hensley LE; Grolla A; Feldmann H
    J Virol; 2009 Jul; 83(14):7296-304. PubMed ID: 19386702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy.
    Marzi A; Ebihara H; Callison J; Groseth A; Williams KJ; Geisbert TW; Feldmann H
    J Infect Dis; 2011 Nov; 204 Suppl 3(Suppl 3):S1066-74. PubMed ID: 21987743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular and humoral immunity to Ebola Zaire glycoprotein and viral vector proteins following immunization with recombinant vesicular stomatitis virus-based Ebola vaccine (rVSVΔG-ZEBOV-GP).
    Raabe V; Lai L; Morales J; Xu Y; Rouphael N; Davey RT; Mulligan MJ
    Vaccine; 2023 Feb; 41(8):1513-1523. PubMed ID: 36725433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ebola virus glycoprotein Fc fusion protein confers protection against lethal challenge in vaccinated mice.
    Konduru K; Bradfute SB; Jacques J; Manangeeswaran M; Nakamura S; Morshed S; Wood SC; Bavari S; Kaplan GG
    Vaccine; 2011 Apr; 29(16):2968-77. PubMed ID: 21329775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High dose of vesicular stomatitis virus-vectored Ebola virus vaccine causes vesicular disease in swine without horizontal transmission.
    Morozov I; Monath TP; Meekins DA; Trujillo JD; Sunwoo SY; Urbaniak K; Kim IJ; Narayanan SK; Indran SV; Ma W; Wilson WC; O'Connor C; Dubey S; Troth SP; Coller BA; Nichols R; Martin BK; Feldmann H; Richt JA
    Emerg Microbes Infect; 2021 Dec; 10(1):651-663. PubMed ID: 33719915
    [No Abstract]   [Full Text] [Related]  

  • 11. Single-Dose Trivalent VesiculoVax Vaccine Protects Macaques from Lethal Ebolavirus and Marburgvirus Challenge.
    Matassov D; Mire CE; Latham T; Geisbert JB; Xu R; Ota-Setlik A; Agans KN; Kobs DJ; Wendling MQS; Burnaugh A; Rudge TL; Sabourin CL; Egan MA; Clarke DK; Geisbert TW; Eldridge JH
    J Virol; 2018 Feb; 92(3):. PubMed ID: 29142131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus.
    Mire CE; Matassov D; Geisbert JB; Latham TE; Agans KN; Xu R; Ota-Setlik A; Egan MA; Fenton KA; Clarke DK; Eldridge JH; Geisbert TW
    Nature; 2015 Apr; 520(7549):688-691. PubMed ID: 25853476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of a Bivalent Vaccine Capable of Inducing Protection Against Both Ebola and Cross-clade H5N1 Influenza in Mice.
    Wong G; Qiu X; Ebihara H; Feldmann H; Kobinger GP
    J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S435-42. PubMed ID: 26022441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses.
    Geisbert TW; Daddario-Dicaprio KM; Geisbert JB; Reed DS; Feldmann F; Grolla A; Ströher U; Fritz EA; Hensley LE; Jones SM; Feldmann H
    Vaccine; 2008 Dec; 26(52):6894-900. PubMed ID: 18930776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Replicating Single-Cycle Adenovirus Vaccine Against Ebola Virus.
    Anguiano-Zarate SS; Matchett WE; Nehete PN; Sastry JK; Marzi A; Barry MA
    J Infect Dis; 2018 Nov; 218(12):1883-1889. PubMed ID: 29982595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial.
    Huttner A; Dayer JA; Yerly S; Combescure C; Auderset F; Desmeules J; Eickmann M; Finckh A; Goncalves AR; Hooper JW; Kaya G; Krähling V; Kwilas S; Lemaître B; Matthey A; Silvera P; Becker S; Fast PE; Moorthy V; Kieny MP; Kaiser L; Siegrist CA;
    Lancet Infect Dis; 2015 Oct; 15(10):1156-1166. PubMed ID: 26248510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Vesicular Stomatitis Virus-Ebola Virus Postexposure Treatment in Rhesus Macaques Infected With Ebola Virus Makona.
    Marzi A; Hanley PW; Haddock E; Martellaro C; Kobinger G; Feldmann H
    J Infect Dis; 2016 Oct; 214(suppl 3):S360-S366. PubMed ID: 27496978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!).
    Henao-Restrepo AM; Camacho A; Longini IM; Watson CH; Edmunds WJ; Egger M; Carroll MW; Dean NE; Diatta I; Doumbia M; Draguez B; Duraffour S; Enwere G; Grais R; Gunther S; Gsell PS; Hossmann S; Watle SV; Kondé MK; Kéïta S; Kone S; Kuisma E; Levine MM; Mandal S; Mauget T; Norheim G; Riveros X; Soumah A; Trelle S; Vicari AS; Røttingen JA; Kieny MP
    Lancet; 2017 Feb; 389(10068):505-518. PubMed ID: 28017403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single immunization with a monovalent vesicular stomatitis virus-based vaccine protects nonhuman primates against heterologous challenge with Bundibugyo ebolavirus.
    Falzarano D; Feldmann F; Grolla A; Leung A; Ebihara H; Strong JE; Marzi A; Takada A; Jones S; Gren J; Geisbert J; Jones SM; Geisbert TW; Feldmann H
    J Infect Dis; 2011 Nov; 204 Suppl 3(Suppl 3):S1082-9. PubMed ID: 21987745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlates of vaccine-induced protective immunity against Ebola virus disease.
    Medaglini D; Santoro F; Siegrist CA
    Semin Immunol; 2018 Oct; 39():65-72. PubMed ID: 30041831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.